Cargando…
Patient benefit rate and guarantee time bias in analysis of outcomes for gynecologic oncology patients receiving targeted treatment after somatic tumor genetic testing
Autores principales: | Cathcart, Ann M., Chen, Emerson Y., Bruegl, Amanda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198318/ https://www.ncbi.nlm.nih.gov/pubmed/35719319 http://dx.doi.org/10.1016/j.gore.2022.101019 |
Ejemplares similares
-
Lynch syndrome – Muir-Torre variant: implication in gynecologic oncology
por: Bogani, Giorgio, et al.
Publicado: (2018) -
Surviving the COVID-19 pandemic: early response of a gynecologic oncology unit in Singapore
por: Lim, Yu Hui, et al.
Publicado: (2020) -
How to guarantee the core competencies in redeployment during the patient surge from COVID-19 or other emerging infectious diseases
por: Kang, Sunjoo, et al.
Publicado: (2023) -
Bias and potential premature conclusions regarding the clinical benefits of oXiris in septic adult patients
por: Chen, Jia-Jin, et al.
Publicado: (2023) -
After the Laparoscopic Approach to Cervical Cancer (LACC) trial: Korean Society of Gynecologic Oncology (KSGO) survey
por: Kim, Miseon, et al.
Publicado: (2019)